Cautious Outlook on Moderna: Declining Vaccine Demand and Strategic Challenges Prompt Sell Rating
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
The major COVID variants we've seen so far and which one to look out for right now
Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...
Pharmabiz6h
Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older
Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...
The Globe and Mail36m
Stocks Extend Post-Election Gains Ahead of the FOMC Meeting
Moderna (MRNA) is up more than +3% after reporting Q3 Covid-19 vaccine revenue of $1.8 billion, which is stronger than the consensus of $1.2 billion. Lyft (LYFT) is up more than +29% after reporting ...
Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX
Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX ...
Indiatimes13h
WORLD NEWS
Upon a potential return to the White House, Donald Trump has outlined a series of immediate actions for his first day and second term. These include dismissing legal cases against him, enacting ...